|Bid||7,176.00 x 0|
|Ask||7,178.00 x 0|
|Day's Range||7,146.00 - 7,223.00|
|52 Week Range||6,736.00 - 10,120.00|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||29.42|
|Earnings Date||Apr 30, 2021|
|Forward Dividend & Yield||2.07 (2.87%)|
|Ex-Dividend Date||Feb 25, 2021|
|1y Target Est||78.83|
Dr. Howard Forman, Yale School of Public Health Professor joins the Yahoo Finance Live panel to discuss the latest with the JNJ vaccine.
Michael Darda, Chief Economist & Macro Strategist at MKM Partners joins Yahoo Finance Live to discuss the outlook for economic recovery after U.S. regulators called for a pause in the use of Johnson & Johnson’s COVID-19 vaccine.
A UK study into using different COVID-19 vaccines in two-dose inoculations is being expanded to include shots made by Moderna and Novavax, researchers said on Wednesday. The trial, known as the Com-Cov study, was first launched in February to look at whether giving a first dose of one type of COVID-19 shot, and a second dose of another, elicits an immune response that is as good as using two doses of the same vaccine. The idea, said Matthew Snape, the Oxford University professor leading the trial, "is to explore whether the multiple COVID-19 vaccines that are available can be used more flexibly".